Mallinckrodt Pharma agrees to pay $100M to settle price hike suit: 4 takeaways

Mallinckrodt will pay $100 million to settle Federal Trade Commission claims that its U.S. subsidiary, Questcor, illegally raised the price of its autoimmune drug by 85,000 percent and purchased the rights to a cheaper version of the drug to keep it off the market, reports Bloomberg.

Here are 4 things to know.

1. Questcor purchased the rights to H.P. Acthar Gel — used to treat multiple sclerosis, infantile spasms and other life-threatening conditions — and raised the drug's price from $40 a vial to more than $34,000, according to a statement from the FTC.

2. In 2012, Questcor purchased the rights to a similar drug, Novartis' Synacthen — which was being sold in Europe and Canada at a much cheaper price — to monopolize the market, alleges the FTC.

3. Mallinckrodt acquired Questcor for $5.6 billion in 2014 and allowed the anticompetitive behavior to continue, according to the report.

4. Mallinckrodt reached a settlement agreement with the attorneys general in New York, Alaska, Maryland, Texas and Washington state, as well as with the FTC, reports Bloomberg. Each state will receive $10 million from the settlement and $2 million is set aside for attorney's fees, according to the FTC.

 More articles on supply chain:

Supply chain tip of the week: How to manage excessive drug price hikes
Drug shortage spurs FDA to allow use of topical gel approved in Europe
Novartis to consider more US investments amid Trump tax cuts

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars